| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/04/2000 | US6046169 Inhibitors of factor XA |
| 04/04/2000 | US6046168 Peptide inhibits blood triglyceride level |
| 04/04/2000 | US6046167 For controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion |
| 04/04/2000 | US6046166 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/04/2000 | US6046164 Therapeutic agent for diseases of periodontal tissue |
| 04/04/2000 | US6046163 Cyclosporin formulation |
| 04/04/2000 | US6046162 Suppression of cell proliferation by decorin |
| 04/04/2000 | US6046161 Use of hemoglobin in the treatment of cardiogenic shock |
| 04/04/2000 | US6046160 Composition and method for enhancing wound healing |
| 04/04/2000 | US6046158 Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
| 04/04/2000 | US6046157 Modulation of TGF-β by recombinant TGF-β type II receptor polypeptides |
| 04/04/2000 | US6046049 Compound 8 to 30 nucleobases in length targeted to 3' untranslated region of nucleic acid which encodes human phosphatidyl inositol 3' kinase p110 delta isoform found in leukocytes; diagnosis, treatment of related diseases |
| 04/04/2000 | US6046047 Genetic construct encoding a chimeric protein with a domain which binds and crosslinks a synthetic, membrane permeable, non-peptide ligand and domain to cause cellular localization of complex; for gene therapy and inducible gene expression |
| 04/04/2000 | US6046044 Cisplatin resistance proteins |
| 04/04/2000 | US6046036 For increasing survival rate of non-target cells such as hematopoietic cells when contacted with anticarcinogenic/dna-damaging agents during multiagent chemotherapy protocols or in fanconi's anemia |
| 04/04/2000 | US6046035 Polynucleotides encoding a cardiotrophin-like cytokine |
| 04/04/2000 | US6046034 Thermostable variants of human interferon-γ(IFN-γ) |
| 04/04/2000 | US6046033 Basic osteoblast growth factor II (bOGF-II) |
| 04/04/2000 | US6046031 Metalloproteinases |
| 04/04/2000 | US6046030 For the treatment of neurological disorders such as alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, among others and diagnostic assays for such |
| 04/04/2000 | US6046029 Nucleic acids encoding human fatty acid synthase-like protein |
| 04/04/2000 | US6046027 Human retinoid binding protein |
| 04/04/2000 | US6046015 Modulating Robo: ligand interactions |
| 04/04/2000 | US6046009 Diagnosis and treatment of glaucoma |
| 04/04/2000 | US6046007 Administering to the subject an effective amount of a polypeptide having crma biological activity and under suitable conditions such that t cells remain viable. |
| 04/04/2000 | US6045999 Transcription factor E2F-4 |
| 04/04/2000 | US6045997 Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof |
| 04/04/2000 | US6045831 Nuclear inhibitor I-92 and its use for the production of a medicament |
| 04/04/2000 | US6045829 Having increased rate and uniformity of absorption in vivo |
| 04/04/2000 | US6045826 Antioxidant/antiaging medicinal or cosmetic mixture for skin disorder prophylaxis |
| 04/04/2000 | US6045818 Cell growth substrates with tethered cell growth effector molecules |
| 04/04/2000 | US6045809 A drug mixture consisting of prolamines and polymer films derived from prolamines with good bioavailability and therapeutic efficacy; treating inflammation |
| 04/04/2000 | US6045803 Administering to an avian a recombinant herpesvirus of turkeys for expressing an antigenic polypeptide to treat viral diseases |
| 04/04/2000 | US6045802 Antitumor agents treating cancer |
| 04/04/2000 | US6045796 Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| 04/04/2000 | US6045795 Methods and compositions for ameliorating the symptoms of sepsis |
| 04/04/2000 | US6045794 Platelet-activating factor acetylhydrolase |
| 04/04/2000 | US6045793 Recombinant ribonuclease proteins |
| 04/04/2000 | US6045792 Human proteins kinases |
| 04/04/2000 | US6045789 Bystander effect tumoricidal therapy by expressing an HSV-tk gene |
| 04/04/2000 | US6045788 Method of stimulation of immune response with low doses of IL-2 |
| 04/04/2000 | CA2246162C Modulation of th1/th2 cytokine expression by ribavirin.rtm. and ribavirin.rtm. analogs in activated t-lymphocytes |
| 04/04/2000 | CA2173878C Polynucleotide for treating systemic lupus erythematosus |
| 04/04/2000 | CA2172819C Use of anti-idiotypic antibodies to prevent hyperacute rejection of xenografts |
| 04/04/2000 | CA2155933C Pulmonary administration of scr1 and other complement inhibitory proteins |
| 04/04/2000 | CA2140053C Collagen-based injectable drug delivery system and its use |
| 04/04/2000 | CA2127331C Motilin-like polypeptides that inhibit gastrointestinal motor activity |
| 04/04/2000 | CA2002540C Dna sequence coding for the human ix factor or a similar protein, expression vector, transformed cells, process for the preparation of ix factor and products obtained |
| 04/04/2000 | CA1340948C Peptidylaminodiols |
| 04/04/2000 | CA1340942C Processes for the treatment of vascular disease |
| 04/04/2000 | CA1340940C Peptidylaminodiols |
| 04/02/2000 | CA2284364A1 Biomedical devices with antimicrobial coatings |
| 04/01/2000 | CA2284387A1 Use of peptide preventing skin intolerance reactions, notably in cosmetic compounds |
| 03/30/2000 | WO2000017641A1 Gpr10 as a target for identifying weight modulating compounds |
| 03/30/2000 | WO2000017400A1 ANTISENSE MODULATION OF cREL EXPRESSION |
| 03/30/2000 | WO2000017382A1 Methods and compositions relating to bone-derived growth factor-like polypeptides |
| 03/30/2000 | WO2000017375A2 Method to treat haemophilia by in vivo gene therapy with retroviral vectors |
| 03/30/2000 | WO2000017373A1 Recombinant celo virus and celo virus dna |
| 03/30/2000 | WO2000017370A1 HUMAN COMPLEMENT C3-DEGRADING POLYPEPTIDE FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| 03/30/2000 | WO2000017369A2 Alzheimer's disease secretase |
| 03/30/2000 | WO2000017366A2 Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug |
| 03/30/2000 | WO2000017362A1 Human interleukin-b50, therapeutic uses |
| 03/30/2000 | WO2000017361A2 Interferon-epsilon |
| 03/30/2000 | WO2000017360A1 Cystine knot growth factor mutants |
| 03/30/2000 | WO2000017358A2 Human chaperone proteins |
| 03/30/2000 | WO2000017357A1 Methods and compositions relating to egf-repeat-containing polypeptides |
| 03/30/2000 | WO2000017356A2 Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof |
| 03/30/2000 | WO2000017355A2 Human cytoskeleton associated proteins |
| 03/30/2000 | WO2000017354A1 Human isre-binding protein |
| 03/30/2000 | WO2000017353A1 Ucp4 |
| 03/30/2000 | WO2000017349A1 A HUMAN Hsg III GENE |
| 03/30/2000 | WO2000017348A1 G protein-coupled receptor agonists or antagonists |
| 03/30/2000 | WO2000017346A2 Hairpin hybridizer molecules for modulation of gene expression |
| 03/30/2000 | WO2000017345A1 Ly6h gene |
| 03/30/2000 | WO2000017334A2 Analysis of ligand activated nuclear receptors i(in vivo) |
| 03/30/2000 | WO2000017328A2 Fibrils |
| 03/30/2000 | WO2000017325A1 Trophoblast cell preparations |
| 03/30/2000 | WO2000017240A1 Hmw endostatin for inhibiting the growth of tumours and capillary proliferation and for diagnosing vascular and tumour diseases |
| 03/30/2000 | WO2000017239A1 Purification of fibrinogen from fluids by precipitation and hydrophobic chromatography |
| 03/30/2000 | WO2000017234A1 Purification of fibrinogen from milk by use of cation exchange chromatography |
| 03/30/2000 | WO2000017233A2 Genes of the 1-desoxy-d-xylulose biosynthetic pathway |
| 03/30/2000 | WO2000017231A1 Ethylamine derivatives |
| 03/30/2000 | WO2000017229A1 Process for the preparation of n2-(1(s)-carboxy-3-phenylpropyl)-l-lysyl-l-proline |
| 03/30/2000 | WO2000017228A2 Stereoselective process for enalapril |
| 03/30/2000 | WO2000017227A1 Method for purification of alpha-1 proteinase inhibitor |
| 03/30/2000 | WO2000017226A1 Synthetic peptides, conjugation reagents and methods |
| 03/30/2000 | WO2000017225A2 A small protein that interacts with a ribonucleotide reductase subunit and uses thereof |
| 03/30/2000 | WO2000017224A1 ANTISENSE MODULATION OF RhoC EXPRESSION |
| 03/30/2000 | WO2000017222A1 31 human secreted proteins |
| 03/30/2000 | WO2000017220A1 Antisense modulation of fan expression |
| 03/30/2000 | WO2000016848A1 Systems and methods for treating ischemia |
| 03/30/2000 | WO2000016809A1 ANTISENSE MODULATION OF RhoB EXPRESSION |
| 03/30/2000 | WO2000016808A2 Antibody directed enzyme prodrug therapy (edept) with glucoronidase |
| 03/30/2000 | WO2000016804A1 METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| 03/30/2000 | WO2000016801A1 Methods of downmodulating the immune response to therapeutic proteins |
| 03/30/2000 | WO2000016800A2 Methods of treating chronic pain |
| 03/30/2000 | WO2000016799A1 Methods of treating chronic pain |
| 03/30/2000 | WO2000016797A2 Use of glp-1 or analogs in treatment of stroke |
| 03/30/2000 | WO2000016796A1 Chemokine receptor antagonist and cyclosporin in combined therapy |
| 03/30/2000 | WO2000016795A1 Preventives and/or remedies for obesity |